Transformative cell therapy programs
We are currently pursuing the creation of new cell therapies in two therapeutic areas: neurology and ophthalmology
Neurology
What if we could replace the cells lost in Parkinson鈥檚 disease and restore functionality?
Parkinson鈥檚 disease is a progressive neurodegenerative disorder caused by the loss of dopamine-producing cells in the brain. As the world鈥檚 second-most common neurodegenerative disorder, it impacts millions of people globally, yet the standard of care has seen only nominal improvement in 60 years. We鈥檙e trying to change that.
Go deeper: learn more about our bemdaneprocel trial in the treatment of Parkinson鈥檚 disease.
Ophthalmology
What if we could restore a person鈥檚 vision loss due to retinal disease?
Inherited Retinal Diseases (IRD) are the leading cause of vision loss in people aged 15-45, caused by the loss of light-sensing photoreceptor cells in the retina.
Currently in clinical development, our ophthalmology program OpCT-001鈥攊n partnership with Opsis Therapeutics and FUJIFILM Cellular Dynamics (FCDI)鈥攊s investigating the development of PSC-based therapies for ocular diseases including primary photoreceptor diseases.
Go deeper: understand what we鈥檙e developing for the treatment of primary photoreceptor disease.
Collaborations with like-minded companies and institutions
Creating cell therapies is a team sport
It takes a team to develop cell therapies. Discovering, developing and delivering impactful cell therapies is a tremendous challenge. We find great value in partnering with companies that share our ambition, values and mission.
- Opsis Therapeutics, a joint venture of FUJIFILM Cellular Dynamics, Inc. (FCDI), has a singular focus on creating best-in-class cell replacement therapies targeting retinal diseases. Forged in 2021, this collaboration aims to combine the cell therapy research expertise of Opsis FCDI with SA国际传媒鈥檚 clinical and regulatory development expertise to advance cell therapies for patients with IRD and AMD.
- Through our collaboration with Editas Medicine, we are leveraging their CRISPR genome editing technology to develop engineered iPSC cells that have the potential to carry out an array of functions within the body, such as delivering a therapeutic payload.
- Our collaboration with Senti Biosciences, a leading gene circuit company, enables us to enhance our cell+gene platform by precisely sensing and responding to disease state and therapeutic payload expression.
